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The Case for Proteomics and Phospho-Proteomics
in Personalized Cancer Medicine
Sophia Doll, Florian Gnad, and Matthias Mann*
The concept of personalized medicine is predominantly been pursued through
genomic and transcriptomic technologies, leading to the identiﬁcation of
multiple mutations in a large variety of cancers. However, it has proven
challenging to distinguish driver and passenger mutations and to deal with
tumor heterogeneity and resistant clonal populations. More generally, these
heterogeneous mutation patterns do not in themselves predict the tumor
phenotype. Analysis of the expressed proteins in a tumor and their
modiﬁcation states reveals if and how these mutations are translated to the
functional level. It is already known that proteomic changes including
posttranslational modiﬁcations are crucial drivers of oncogenesis, but
proteomics technology has only recently become comparable in depth and
accuracy to RNAseq. These advances also allow the rapid and highly sensitive
analysis of formalin-ﬁxed and paraﬃn-embedded biobank tissues, on both the
proteome and phosphoproteome levels. In this perspective, pioneering mass
spectrometry-based proteomic studies are highlighted that pave the way
toward clinical implementation. It is argued that proteomics and
phosphoproteomics could provide the missing link to make omics analysis
actionable in the clinic.
1. Introduction
Cancer, “The Emperor of all Maladies,”[1] was responsible for
nine million deaths worldwide in 2018, despite harsh treatments
from which many patients do not derive any beneﬁt.[2] The poor
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clinical outcome for most cancer types
originates from a diverse array of factors,
including late diagnosis, tumor hetero-
geneity, metastasis, lack of targeted treat-
ment options and resistance to therapy,
tumor recurrence, and a failure to trans-
late preclinical breakthroughs intomean-
ingful patient beneﬁt.
The rapidly decreasing costs of
next-generation sequencing (NGS)
technologies[3] have triggered an explo-
sion of genomic data, improving our
overall understanding of cancer. The
Cancer Genome Atlas (TCGA)[4] and the
International Cancer Genome Consor-
tium (ICGC)[5] have surpassed the 1000
Genomes Project by sequencing thou-
sands of tumors across diﬀerent cancer
types. Comprehensive genetic proﬁling
of tumor samples has uncovered novel
oncogenes and tumor suppressor genes
by comparing their mutation frequen-
cies with the background mutation
rate,[6] or by detecting mutation proﬁles
with signiﬁcant bias toward certain mutation types such as non-
silent,[7] functional,[8] or hotspot[9] mutations. In turn, this has
transformed the target selection process inmany pharmaceutical
companies and led to the development of personalized sequenc-
ing tests that are increasingly being oﬀered in a clinical setting.
For example, TCGA data revealed an enormous mutation bur-
den in epigenetic regulators,[10] including the SWI/SNF complex
subunits protein polybromo-1 (PBRM1) and AT-rich interactive
domain-containing protein 1A (ARID1A), which are mutated in
approximately one third of clear cell renal cell carcinomas[11] and
endometrial carcinomas.[12] Similarly, a signiﬁcant proportion of
bladder cancer patients showed mutations in multiple genes in-
cluding histone-lysine N-methyltransferase 2D (MLL2), cyclin-
dependent kinase inhibitor 1 (CDKN1A), general transcription
and DNA repair factor IIH helicase subunit XPD (ERCC2), or co-
hesin subunit SA-2 (STAG2) previously not directly linked to this
disease.[13] It has been estimated that a comprehensive catalog of
cancer genes requires the analysis of2000 tumors for each of at
least 50 tumor types, corresponding to 100 000 tumors.[14] Given
the rate of tumor genome sequencing, the available NGS data are
already close to this magnitude.
In many cases, however, the involvement of these mutated
genes was already known before the sequencing boom.[15] Over-
all, NGS of the tumor genome identiﬁed actionable genes in
about one third of cancer patients, but only a fraction of patients
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showed clinical beneﬁt.[16,17] Extending NGS to the transcript
level (RNAseq) should provide a more comprehensive picture
of the tumor landscape. Applied to the detection of gene fusions
and to the diﬀerential expression, it has elucidated potential
biomarkers and previously unknown biology in combination
with DNA sequencing.[18,19] In this way, exome sequencing
uncovered mutations in kelch-like ECH-associated protein 1
(KEAP1) in 20% of lung adenocarcinomas,[20] while matching
RNA sequencing revealed a constitutively activated transcrip-
tional response of 27 genes as a potential biomarker signature
for KEAP1 mutant tumors.[21]
This illustrates that the limitations of genomics and transcrip-
tomics restrict our ability to fully comprehend the pathophysiol-
ogy and complexity of cancer. Instead, panomics, the integration
of multiple “omic” approaches may be better able to decipher
causal relationships.[22] Furthermore, it has become clear that
the development and complexity of cancer cannot be explained
simply by genetic alterations and transcriptional changes alone.
Instead, the investigation of proteins and their posttranslational
modiﬁcations (PTMs)—the driving molecular entities in our
cells—is necessary to provide insight into perturbed disease
states. Transcript expression does not necessarily correlate with
protein abundance,[23,24] and the action and dynamics of proteins
including PTM-mediated processes, subcellular localization,
and regulatory mechanisms dictating protein accumulation
or degradation are invisible to genomics-based approaches.
Thus, developing methods to directly measure and annotate
protein abundance, interaction, localization, and modiﬁcation
states may oﬀer new insights into the pathophysiology of
tumors and aid in the identiﬁcation and validation of novel drug
targets.
Protein mass spectrometry (MS) has emerged as the technol-
ogy of choice for large-scale and unbiased proteomic analyses.[25]
Recent groundbreaking technological improvements now allow
the analysis of the proteome at a large scale and with short
turnaround times.[25] These advances enable the measurement
of nearly complete proteomes, as more than 12 000 proteins
and more than 10 000 sites of diﬀerent PTMs can be identi-
ﬁed and quantiﬁed in complex cellular systems, including clin-
ical samples.[26–30] Proteomics has also become highly sensitive,
requiring minute sample amounts (<10–100 µg) in cell culture
as well as in clinical samples.[31,32] Given these technological ad-
vances, MS-based proteomics has already been applied to clinical
cancer cohorts.[33–35] However, these workﬂows were highly spe-
cialized and not meant to be used in the clinic.
Here, we advocate the broad adoption of proteomics in
oncological research and clinical settings. We believe that
robust, highly sensitive, and speciﬁc personalized proteomic
technology can be developed to proﬁle tumor-speciﬁc ex-
pression of proteins and PTMs. By combining proteomic
data with genomic and clinical data, the ultimate aim is to
generate a personalized panomics proﬁle for each patient to
better inform treatment decisions.[22] Large initiatives such
as the Obama Precision Medicine program[36,37] highlight
the importance of taking individual molecular variability into
account. In this way, patients who are most likely to respond
and beneﬁt from a given treatment may be better distinguish-
able from those who will only suﬀer from detrimental side
eﬀects.[38,39]
2. Challenges of Translating Genomics Data into
Clinical Use
The genomic interrogation of diverse tumor types has led to
the discovery of the genetic basis of their underlying abnor-
malities. In the classical case of the Philadelphia chromosome,
a translocation causes chronic myeloid leukemia through the
constitutively active BCR-ABL fusion—one of the ﬁrst genetic
alterations that could be linked to pathophysiology.[40] Blocking
this molecular perturbation with tyrosine kinase inhibitors,
such as Imatinib, was a pioneering achievement for targeted
therapy in cancer.[40] Other successful implementations of
targeted therapies, resulting from their genetic characterization,
include blocking receptor tyrosine-protein kinase erbB-2 (HER2)
in breast cancers with Herceptin,[41] inhibiting anaplastic
lymphoma kinase (ALK) in lymphoma with Crizotinib,[42] or
interrupting epidermal growth factor receptor (EGFR) activity
in lung cancer with Geﬁnitib.[43] Although most of these devel-
opments predate modern sequencing technology, NGS can be
eﬃciently utilized as a discovery and diagnostic tool on which
targeted therapies can be based. The comprehensiveness of NGS
technologies routinely allows the detection of the entire spec-
trum of genetic abnormalities. This is important as tumors may
either result from a single, initial mutation, such as the GTPase
K-RASG12D or Phosphoinositide-3-kinase PIK3CAH1057R muta-
tion in the PI3 kinase pathway[44] or rely on the concerted action
of many genetic alterations for uncontrolled cell growth and
proliferation.
Despite the remarkable success of genomic-based approaches,
the majority of tumors do not present a clearly actionable ge-
netic alteration. Furthermore, patients often do not respond to
such targeted genetic therapies.[45,46] In many cases, poor or no
responses can be traced back to heterogeneity of the tumors. This
subclonal architecture can arise through intercellular genetic in-
stability, followed by selective outgrowth of clones that have a phe-
notypic advantage during treatment and within the given micro-
environmental context.[47] Deep sequencing from single cells is a
promising technology to decipher the complexity of tumors.[48]
However, the resulting complex and heterogeneous mutation
spectrum usually presents even greater challenges in selecting
a treatment because it is diﬃcult to predict whether the presence
of genetic abnormalities will translate into downstream levels of
gene expression and into the phenotype of cells and tissues. Ob-
viously, genomic and transcriptomic changes can only have an
impact on the phenotype if they are indeed translated into the
proteomic level.
At the methodological level, an obstacle to using RNAseq data
in the clinic is the preservation of tumor biopsies as formalin-
ﬁxed and paraﬃn-embedded (FFPE), where RNA is unstable
resulting in poor sample quality.[49] Although alternatives exist,
FFPE is by far the most common storage modality for tissue
biopsies due to its capabilities for long preservation and its
amenability to H&E staining and immunohistochemistry. It
is estimated that about half a billion archived FFPE cancer
tissue samples exist to date and this number is rapidly rising.[50]
These immense archives of material present an invaluable
resource for studying the underlying molecular mechanisms
of cancer, testing known biomarkers and uncovering new
ones.
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Figure 1. MS-based proteomic workﬂow. Cancer samples, such as FFPE tissues, blood plasma, or cells are analyzed using automated sample preparation
methods and analyzed by high resolution MS. The generated proteomic data are analyzed using sophisticated but automated bioinformatic workﬂows
resulting in a set of several thousand identiﬁed and quantiﬁed proteins.
3. The Promise of Proteomics
In almost all cases, proteins are the functional biological enti-
ties in cells, working in concert with each other as molecular
machines or in pathways, ensuring that each cell performs its
speciﬁc biological functions. Drugs targeting mitogen-activated
protein kinase 1 (MAPK), PI3K, serine/threonine-protein kinase
B-raf (BRAF), vascular endothelial growth factor (VEGF), ALK,
and EGFR inhibit their targets directly at the protein level—and
not at the gene level.[15] The phosphorylation intensities of
associated substrates are commonly used as a proxy to detect
aberrant kinase activities. Phosphoproteomics measures the
identity and quantity of tens of thousands of phosphorylation
sites, serving as an ultimate read-out of the activity of kinases
and altered signaling pathways, which are among the most im-
portant alterations in oncogenic transformation. Consequently,
most of the laboratory tests performed for diagnosis and therapy
are in general based on proteins.[51] In pathology, immunohisto-
chemistry to stain proteins in cancer tissues is still the mainstay
for tumor classiﬁcation and decisions on therapy. Thus, protein
analysis plays a central role in current clinical practice and
diagnostics. Proteins can be localized in diﬀerent subcellular
compartments, exhibit regulated degradation, and can be fur-
ther modiﬁed by PTMs. These events happen downstream of
gene expression, and therefore transcript abundance does not
necessarily correlate with protein abundance and activity.[23] It
is thus important to directly measure protein abundance and
modiﬁcations to characterize the disease status.
On a practical level, proteins are more stable than oligonu-
cleotides, especially RNA.[52,53] This makes proﬁling of proteins
inherently more robust and forgiving of sample quality. Today,
protein abundance is determined in high-throughput platforms
that analyze proteins in automated antibody-based workﬂows.
However, this is almost always restricted to individual and al-
ready known proteins, negating the possibility to uncover novel
biomarkers. In contrast, MS-based proteomics measures thou-
sands of proteins at once (ideally the entire expressed proteome)
and is unbiased in this sense. Furthermore, this technology does
not depend on protein epitopes being preserved, unlike antibody-
based methods.
Taking advantage of the stability and ease-of-handling of both
unmodiﬁed or posttranslationally modiﬁed proteins, extraction
from FFPEmaterial is possible in a robust manner for MS-based
analysis. The comparison of FFPE to fresh tissues did not reveal
major quantitative or qualitative diﬀerences at the protein or
PTM level, including phosphorylation and even 30-year old FFPE
tissues have been analyzed successfully.[54,55] Thus MS-based
proteomics holds great promise for discovering new biomarkers
and improving prognostic and predictive power for clinicians.
4. Recent Technological Advances of Mass
Spectrometry-Based Proteomics
Because of its high speciﬁcity, sensitivity, and accuracy, MS has
emerged as the technology of choice for large-scale and unbiased
proteomic analyses, presenting a promising solution for the chal-
lenges described.[25]
A typical MS-based proteomic workﬂow ﬁrst requires the
lysis of the biological source of material, in order to eﬃciently
extract proteins (Figure 1). This step incorporates heating to
increase lysis eﬃciency and denature proteins, and is particularly
important for de-crosslinking FFPE samples. Cysteines of the
extracted proteins are then reduced and alkylated to disrupt
disulﬁde bridges prior to digestion. Lys-C in combination with
trypsin are generally the enzymes of choice due to their high
cleavage speciﬁcity to lysines and arginines, yielding a deﬁned
set of identiﬁable peptides as search space for subsequent
search algorithms. These sample preparation steps can now
be automated and performed in a single device (“in-StageTip”
method[56]), considerably reducing sample preparation time,
contamination and material loss while increasing reproducibil-
ity and throughput. The investigation of PTMs using MS
requires additional enrichment steps and hence larger starting
materials (by a factor 10–100) as PTM sites are generally sub-
stoichiometrically occupied. Common enrichment strategies
use aﬃnity puriﬁcation based on charge properties or antibody
recognition.[57,58] Phosphorylation is one of the most important
and commonly studied PTMs (see statistics of PhosphoSitePlus;
www.phosphosite.org).[59] This has prompted the development
of highly eﬀective protocols, such as the EasyPhos method.[60,61]
High-throughput enrichment methods using robotic assistance
are also becoming possible.[62] For instance, the AssayMAP
robotic technology (Agilent Technologies) enables the enrich-
ment of phosphopeptides from 96 samples in only 1 h.[63]
Peptides are loaded onto a C18-bead ﬁlled capillary column
and then subjected to high performance liquid chromatography
(HPLC) separation, before electrospray ionization and transfer to
Proteomics Clin. Appl. 2019, 13, 1800113
C© 2019 The Authors. Proteomics – Clinical Application
published by WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.1800113 (3 of 10)
www.advancedsciencenews.com www.clinical.proteomics-journal.com
the mass spectrometer. For maximum sensitivity, column diam-
eters and ﬂowrates are chosen to be as low as possible, which
can compromise robustness of the measurement. Novel LC sys-
tems have signiﬁcantly increased reliability and reduced times
between runs to a fewminutes.[64] Hence, themeasurement time
of a mass spectrometer, which remains the most cost-intensive
part of the workﬂow, can be used more eﬃciently.
The MS peptide data can be acquired using diﬀerent methods,
such as data-dependent acquisition (DDA) modes in which
the mass spectrometer automatically fragments the top most
abundant peptide peaks in each scan. Currently, Orbitrap-based
mass spectrometers are dominant, although in our group the
combination of trapped ion mobility with time of ﬂight MS has
recently shown much promise.[65] Apart from the sensitivity of
a measurement, which determines the needed input material,
another crucial parameter is the dynamic range—meaning the
ability tomeasure low abundance proteins in the presence of very
highly abundant ones. For instance, in muscle tissue, protein
copy numbers can range from tens to more than many million
per cell.[28,51,66] New MS acquisition methods, such as “BoxCar,”
can extend the accessible dynamic range at least tenfold.[67]
Data-independent acquisition (DIA) measurements such as
“sequential window acquisition of all theoretical mass spec-
tra” (SWATH) isolate multiple peptides within a speciﬁc m/z
range.[68,69] Selected peptides are then co-fragmented and mea-
sured simultaneously. The resulting complex fragment spectra
can be analyzed using appropriate bioinformatics methods.[70] A
principal attraction of DIA is that it reduces the “missing value
problem,” which is especially pertinent in clinical studies. Recent
technological advances have made DIA increasingly competitive,
featuring high dynamic range, reproducible and accurate protein
quantiﬁcation with CVs reaching 10% or below.[71,72]
Targeted proteomic methods are used to analyze a limited
set of predeﬁned peptides with high reproducibility and speci-
ﬁcity. They come in diﬀerent ﬂavors, including single, multiple,
and parallel reaction monitoring (SRM, MRM, PRM),[73,74] but
by their nature they are not applicable to the discovery of novel
biomarkers.
The advances in MS instrumentation go hand in hand with
the development of required software. These tools have become
increasingly powerful and user-friendly, enabling comprehensive
analysis of large proteomic datasets and their integration with
other “omics” data layers.[75]
Together, these technological advances have drastically im-
proved all steps of today’s MS workﬂow, and have enabled the
characterization of nearly complete proteomes in recent years.[25]
The identiﬁcation and quantiﬁcation of more than 10 000 diﬀer-
ent proteins from minute amount of material, including FFPE
tissues, is becoming feasible.[33,76–78] Thus, MS-based proteomics
now enables robust, reproducible, and in-depth proﬁling of the
proteome with fast turnaround times, for instance requiring only
4 h for blood plasma proteomics and two and a half days for
tissues.[79,80]
5. MS-Based Proteomics in Cancer Discovery
As the sensitivity of MS has substantially increased in recent
years, the technology has begun to enable the elucidation of
previously unknown alterations in cancer and to be used as a
classiﬁcation tool of diﬀerent cancer types. In our laboratory,
the combination of tissue proteomics and machine-learning
classiﬁed diﬀuse large B-cell lymphoma depending on the cell of
origin[81,82] and helped to identify most suitable cell line models
for ovarian cancer research.[83]
But even before MS was able to capture nearly complete
proteomes, several discoveries with translational potential have
been made. For example, in 2007 a global survey of phospho-
tyrosine signaling in non-small cell lung cancer (NSCLC) cell
lines and tumors revealed unusually high activities of ALK
and proto-oncogene tyrosine-protein kinase ROS (ROS).[84]
Follow-up western blotting, RT-PCR, and DNA sequencing in
these samples revealed oncogenic ALK and ROS fusion proteins,
including the fusion of ALK to echinoderm microtubule-
associated protein-like 4 (EML4). Diagnostic tests designed to
screen NSCLC tumors for the presence of rearrangements in
ALK have consequently been commercialized for the selection
of patients for treatment with Crizotinib.[85]
MS-based proteomics may be particularly important in identi-
fying targets in poorly mutated tumors such a pediatric ones. A
recent study showed that malignant pediatric medulloblastomas
do not show profound changes at the genomic and transcrip-
tomic levels, however, using MS-based phosphoproteomics, sub-
stantial diﬀerences were found.[86] The proteomic data classiﬁed
themedulloblastoma patients into subgroups, in which phospho-
rylation sites of MYC were associated with poor outcomes.
Very recently, our group has discovered a ﬁrst functional
biomarker in solid tumors by integrating several proteomic lay-
ers, to study protein signaling, protein interactions, and anti-
gen presentation.[76] We started with the question why a small
subset of women with high grade serous ovarian cancer have
a long disease-free survival after chemotherapy. Expression pro-
teomics revealed that tumors of these women re-expressed the
cancer/testis antigen family 45 (CT45), which is normally not
present in adult tissue. Nothing about the function of CT45 was
known, but interaction proteomics[87] showed that CT45 is asso-
ciated with a protein complex involved in DNA damage signal-
ing. Phosphoproteomics further demonstrated involvement of
the Fanconi anemia signaling pathway. Interestingly, we found
that CT45 likely has a dual mode of action. Through direct in-
teraction with the protein phosphatase 4 complex, CT45 func-
tions as a tumor-intrinsic enhancer of chemosensitivity, render-
ing cells hypersensitive toward carboplatin-based chemotherapy.
Additionally, we identiﬁed CT45 as a naturally presented, cancer-
speciﬁc antigen recognized and targeted by patient-derived cyto-
toxic T-cells (Figure 2). Both of these ﬁndings are of direct clinical
relevance and highlight the versatility of proteomics technology
to identify novel treatment targets for chemo- or immunothera-
peutic regimens.
Almost all tumors are heterogeneous and this presents an ana-
lytical and clinical challenge in oncology. So far this heterogeneity
has almost exclusively been addressed at the oligonucleotide
level. However, with the ever increasing sensitivity of MS-based
proteomics, it is now possible to separately analyze tumor versus
stroma or using laser capture microdissection.[55,88,89] In special
circumstances, it is already possible to obtain relatively deep pro-
teomes from less than 1000 cells.[32] Current development should
make it possible to analyze just a few hundred cells in FFPE
Proteomics Clin. Appl. 2019, 13, 1800113
C© 2019 The Authors. Proteomics – Clinical Application
published by WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.1800113 (4 of 10)
www.advancedsciencenews.com www.clinical.proteomics-journal.com
Figure 2. A multi-level proteomics approach uncovers CT45 as a prognostic biomarker in ovarian cancer and sheds light on its biological role.[75]
material (Coscia et al., in preparation). In the future, MS may
even be able to analyze individual cells, however, through-
put would likely remain relatively low, due to the absence of
bar-coding.
6. MS as a Promising Tool for the Clinic
While MS-based proteomics is already widely accepted as
a discovery tool, recent advances in resolution, robustness,
reproducibility, and speed now also allow envisioning the
implementation of the technology directly in a clinical context.
Please see Table 1 for an overview of promising applications of
MS on clinical studies. Although much work remains to make
the technology fully mature for “clinical-level standards,” there
are now promising developments toward its application in the
clinic.[76,90–93] Furthermore, proteomic data have been used to
predict response to therapies in diﬀerent tumor entities.[94] So
far, the greatest focus has been on the discovery and establish-
ment of protein biomarkers in liquid biopsies, in particular
blood plasma.[95] Blood tests are of particular interest because
of their noninvasive nature compared to invasive surgeries
for obtaining biopsies of cancer tissues. Detection of protein
biomarkers in blood, however, is particularly challenging due to
the complexity of the plasma proteome and the high abundance
range of proteins. These technological challenges as well as
conceptual and study design issues have contributed to the near
absence of novel, MS-derived biomarkers in plasma.[51] However,
new MS workﬂows have recently been developed for fast and
robust[79,96] or very deep measurements of plasma samples
with promising results.[97] Therefore, MS-based proteomics
might enable the future discovery of clinically actionable protein
biomarker patterns in liquid biopsies and answer relevant
clinical questions in a much more speciﬁc manner.
As outlined above, tissues are already very amenable to
MS-based proteomics, and ongoing developments will make
deep proteome coverage increasingly routine. Among other
applications, this makes the technology applicable to “case stud-
ies” of single patients, a well-established paradigm in medicine.
Physicians usually treat patients that have been diagnosed
with a deﬁned cancer type with the same standard treatments
and monitor the outcome. In case of nonresponse, toxicity or
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Table 1.Mass spectrometry-based proteomic and phosphoproteomic clinical cancer studies.
Publication Cancer type Sample type PTM
Zhang et al., Cancer Res., 2004 Ovarian Serum —
Fung et al., Clin. Chem., 2010 Ovarian Serum —
Zhang et al., Nature, 2014 Colorectal Tissue —
Mertins et al., Nature, 2016 Breast Tissue +Phosphorylation
Yu et al., J. Proteome Res., 2016 Ovarian Tissue +Phosphorylation
Kim et al., Nat. Commun., 2016 Prostate EPS-Urine —
Zhang et al., Cell, 2016 Ovarian Tissue +Phosphorylation acetylation
Wang et al., Cell Chem. Biol., 2018 Breast Tissue —
Doll et al.,Mol. Oncol., 2018 Urachal Tissue —
Archer et al., Cancer Cell, 2018 Medulloblastoma Tissue +Phosphorylation acetylation
Coscia et al., Cell, 2018 Ovarian Tissue +Phosphorylation
resistance, they move on to second or third line therapy. In
the cancer genomics ﬁeld, several companion diagnostic (CDx)
tests now support physicians in identifying the appropriate
therapeutic treatment for each patient individually.[98–100] In
particular, several trials have used sequencing for advanced
or chemorefractory cancer patients, however, additional thera-
peutic beneﬁt was modest.[16,101,102] To our knowledge, no such
eﬀorts have been implemented on the basis of high-resolution
MS-based cancer proteomics.
We reasoned that the recent technological advances, would
make MS-based proteomics a powerful tool for uncovering
additional, personalized treatment options for chemorefractory
patients. Given the time constraints in this situation, we de-
veloped a fast workﬂow, taking only 2.5 days from obtaining
the sample to interpreted result, which is much faster than
corresponding oligonucleotide-based technology turnaround
times. We employed this workﬂow for a patient with end-stage
urachal carcinoma patient, who had already received multi-
ple standard chemotherapies for her primary and metastatic
tumor.[80] From the tumor and surrounding tissue, we discovered
a set of upregulated proteins, whose biological roles reﬂected
tumor biology. Among these, the epigenetic regulator lysine
speciﬁc histone demethylase 1 (LSD1) caught our attention,
because it is a promising therapeutic target and the focus of
current drug development eﬀorts in several large pharmaceutical
companies.[103] Complementing the proteomic data with NGS
for mutation calling and a newly developed “clinical knowledge
graph” that integrates vast amounts of diverse information,
helped to guide the therapy decision. Based on this data, the
tumor board approved treatment of the patient with a drug
targeting LSD1. We have already applied our workﬂow to a
number of other chemorefractory patients and we envision that
it can be broadly applied in the future.
7. Proteogenomics: Combining Genomics and
Mass Spectrometry-Based Proteomics Data
The development of personalized medicine will require a closer
integration of omic-based approaches, in particular genomic and
proteomic data, and clinical data.[104] To this end, similar to
TCGA, the National Cancer Institute has launched a clinical pro-
teomic tumor analysis consortium (CPTAC) that aims to develop
and standardize workﬂows to systematically identify and char-
acterize cancer-relevant proteins and their underlying biologi-
cal pathways. The combination of proteomic and genomic data,
termed proteogenomics, suggested novel proteomic tumor sub-
types associated with clinical outcome.[33–35] Of note, protein lev-
els could not be predicted from genomic or transcriptomic data,
emphasizing the importance of studying the actual molecular ac-
tors within a cellular system. A link between protein acetylation
and phosphorylation to deﬁciencies in homologous recombina-
tion was identiﬁed in ovarian cancer patients.[35] Since homolo-
gous recombination deﬁciency is associated with susceptibility
to PARP inhibitors and improved survival, this suggests a poten-
tial patient stratiﬁcation for therapies.[105,106] Large number of ki-
nases, such as ribosomal protein S6 kinase alpha-5 (RPS6KA5)
and eIF-2-alpha kinase GCN2 (EIF2AK4) were also identiﬁed,
which are aﬀected by common PIK3CAmutations. Furthermore,
cellular tumor antigen p53 (P53)-mutation-associated phospho-
peptides revealed previously unknown functionalities, such as
the regulation of the kinases serine/threonine-protein kinase
greatwall (MASTL) and eukaryotic elongation factor 2 kinase
(EEF2K).
Since transferases, including kinases[107] and epigenetic
regulators,[10] are among the most frequently mutated proteins
in cancer, it is important to examine the interplay between PTMs
and genomic alterations. Bioinformatics resources such as Phos-
phoSitePlus already integrate PTM sites along with somatic mu-
tations and cancer-associated germline variants, illustrating the
importance of uniting genomics with proteomics to better under-
stand the underlying molecular mechanisms of cancer.[108,109]
While, the driving role of receptor tyrosine kinases, as pre-
dicted from their genomic mutation proﬁle, was validated in
a patient-derived xenograft model of breast cancer, genomics
did not explain the occurrence and role of the phosphorylation
events.[110] This shows that druggable phosphorylation events
can readily be uncovered using proteomics. Proteogenomics
is particularly promising in highly mutated tumors, such as
melanoma.[111] As MS-based proteomics generally requires a ref-
erence database to match fragmentation spectra, it can be chal-
lenging to identify mutated peptides that are not present in this
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Figure 3. Panomics-based approach integrating genomic, transcriptomic, and proteomic data with clinical data to better identify therapeutic treatments
for cancer patients.
database. Thus, sequencing the patient and tumor genomes and
creating a personalized reference proteomic reference database
enables the identiﬁcation of individualized mutated peptides,
if they are expressed at the protein level. Putative neoantigens
have already been identiﬁed using proteogenomics and proven
to be successful as vaccines promoting an antitumor immune re-
sponse and they are currently approaching clinical trials.[112,113] A
RNA-aﬃnity proteogenomic approach also distinguished breast
cancer patients with diﬀerent clinical outcomes and thus helped
to guide therapeutic decisions.[114] These studies highlight the
added value of proteogenomic analysis over using genomics-
driven approaches only in the clinical characterization of cancers.
8. Conclusion and Outlook
In 2017 the FDA approved pembrolizumab for the treatment of
any unresectable or metastatic solid tumor with microsatellite
instability.[115] This was the ﬁrst time that a cancer drug was in-
troduced based on genetics rather than tumor site or tissue type.
More generally, omics technologies are transforming the process
of target discovery in pharmaceutical companies, as entire per-
turbed molecular landscapes can now be objectively and com-
prehensively mined. That said, the clinical implementation of
NGS technologies, except for mutation calling, has not gained
the same momentum yet.
We are still far from understanding the entire complexity of
cancer. The most evident challenge for establishing omics tech-
nology as routine methods into the clinic is the complex bi-
ology of cancer. Each tumor is unique, and requires multiple
omics layers to characterize its molecular proﬁle as an interplay
of these layers. In this perspective, we have argued that the value
of molecular characterization for diagnoses and therapies of tu-
mors is now indisputable. Proteomics, including the identiﬁca-
tion of PTMs will indeed provide a crucial missing piece in many
biological conundrums in oncology. So far MS-based proteomics
has been held back by immature technology, but this is clearly
changing rapidly.
One of the challenges of bringing MS-based proteomics into
the clinic is the associated cost and the cutting-edge expertise that
is still required. However, today top-endmass spectrometers cost
half a million to a million dollars and this is not too diﬀerent
from high end imaging equipment that is routinely used in on-
cology. Arguably, with robust instrumentation and high utiliza-
tion, costs could even be signiﬁcantly lower than those technolo-
gies. However, the expertise to operate these instruments and to
analyze the data is still needed. Although this will be the case
for the next future, we hope that more robust instrumentation,
broad training, and standardization will eventually change this
picture. In our own laboratory, the analysis of cancer tissues has
become quite robust, being performed in an automated manner
on a robotic platform. In this way, 12 cancer proteomes can al-
ready be measured per mass spectrometer per day and improve-
ments currently underway in the entire LC MS/MS workﬂow
may soon increase the throughput and robustness further.[64,65]
We envision a future in which genomics, transcriptomics, pro-
teomics, and other omics and clinical data will go hand in hand
to deﬁne the best treatment for the patient (Figure 3).
However, there are still many challenges ahead. Assuming
that the associated avalanche of data can be standardized, pro-
cessed, stored, and securely shared, omics-based personalized
medicine will still face the challenge of false positives or neg-
atives. For example, diﬀerent “state-of-the-art” computational
methods predicting the eﬀects of missense mutations yield in-
consistent results.[116] It is unacceptable that the life of a patient
should hinge on the insuﬃcient development of computational
classiﬁers. The bioinformatics community recognizes this chal-
lenge, and multiple eﬀorts aim to standardize, tune, or combine
computational methods to enhance crucial applications such as
mutation calling.[117] In general, the increasing use of artiﬁcial
intelligence will further empower personalized cancer medicine
by enabling the usage of large data.[118]
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As outlined above, pioneering studies have demonstrated the
potential of MS-based proteomics for biomarker discovery and
clinical applications. Proteomics already created the possibility
for medical doctors and scientists to open up new treatment
options for end stage cancer patients by identifying actionable
therapeutic targets. As the MS technology becomes increasingly
sensitive, the analysis of minute amounts of laser capture mi-
crodissected tissues and even close to single cell analysis will be-
come increasingly realistic. Furthermore, the automation of the
workﬂows will enable the characterization of much larger patient
cohorts and will lead to the identiﬁcation of clinically relevant
biomarkers.
This approach will not only require many technological ad-
vances but also a cultural shift on many levels—in regulatory
agencies, in pharmaceutical companies and, most of all, in the
clinic. It will require an openness toward substantially new ap-
proaches of doctors, as well as health care providers—not least
insurance providers.[119] More clinical data are needed to evaluate
clinical utility of omics testing, so that insurers can make deci-
sions about coverage. Large-scale data collection, however, is im-
peded by uncertain reimbursement policies. This dilemma has
to be resolved to establish omics in the clinic.
By combining large scale and individual genomic, (phos-
pho)proteomic and clinical data we envision a bright future by
providing fundamental insights into the underlying molecular
mechanisms of cancer and oﬀering novel therapeutic strategies
in the ﬁeld of personalized medicine.
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